Top 10 ASX Dividend Stocks for Jun 2026 Download Free Report
Sonal Goyal is a business journalist with nearly five years of experience at Kalkine, where she has specialised in reporting on stocks, broker updates, and corporate press releases. With a master’s in finance, she combines financial knowledge with a sharp news sense, allowing her to quickly identify and deliver the most relevant business stories. Over the years, she has built a reputation for clear, accurate, and insightful reporting that keeps readers informed and ahead of market trends. Outside of her professional life, she enjoys exploring new music and travelling.
Image Source: Shutterstock
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Highlights
• Pro Medicus (ASX: PME) continues to secure high-value, long-duration contracts with leading healthcare institutions in North America and beyond
• The company’s Visage 7 imaging platform is recognised globally as a best-in-class radiology solution with performance characteristics that competitors have struggled to match
• ASX: PME operates a transaction-based revenue model that generates highly predictable, recurring income aligned with imaging volume growth
• The global medical imaging software market is expanding rapidly, driven by growing diagnostic demand, AI integration, and the migration from legacy PACS systems
• Pro Medicus consistently delivers exceptional operating margins, placing it among the most capital-efficient software businesses in the ASX top 200
• Investor interest in ASX: PME remains elevated given its unique combination of quality, growth, and global market positioning
Pro Medicus (ASX: PME) has, over the past decade, built something genuinely rare on the Australian Securities Exchange: a globally competitive, high-margin technology business that sells sophisticated software into one of the most structurally sound demand environments imaginable — medical imaging. While many ASX technology stocks have cycled through phases of hype and disappointment, Pro Medicus has quietly and consistently delivered, winning some of the largest and most prestigious radiology software contracts in the world, expanding its presence across North American healthcare systems, and generating margins that would make software businesses in any sector envious.
The story of ASX: PME is one that Australian investors have come to regard with a mixture of admiration and calculation, because at any given moment the question is not whether the business is high quality — that much is beyond serious dispute — but whether the market’s pricing of that quality leaves room for ongoing returns. It is a conversation that has been reset repeatedly as the company continues to grow its contract base and demonstrate that its addressable market is larger and more durable than many initially assumed. In a market that has grown more selective about which technology businesses deserve premium valuations, Pro Medicus keeps presenting fresh evidence for its own case.
Why the Company Is in Focus
Pro Medicus remains at the forefront of ASX investor attention for reasons that go beyond sentiment. The company’s ongoing cadence of contract announcements — major multi-year agreements with leading US academic medical centres, integrated delivery networks, and regional health systems — provides a steady stream of material news that both validates the business model and expands the recurring revenue base in concrete, measurable ways.
Each new contract won by ASX: PME typically comes with a multi-year minimum term and a transaction-based pricing structure, meaning that healthcare institutions commit to paying Pro Medicus a fee for every imaging study processed through the Visage 7 platform. As imaging volumes at these institutions grow — driven by demographic trends, expanding diagnostic capabilities, and the broadening of imaging applications — so too does Recce’s revenue from each contract. This compounding dynamic gives Pro Medicus a very different growth profile from traditional enterprise software companies that rely purely on user seat counts or annual licence renewals.
The company is also in focus because the medical imaging software market is in the midst of a significant technological transition. Legacy picture archiving and communication systems (PACS) that have underpinned hospital radiology departments for decades are reaching end-of-life, creating a replacement cycle that Pro Medicus has been exceptionally well-positioned to capture. Its streaming architecture, which delivers images from the cloud with speed and fidelity that legacy systems cannot match, is a technically superior offering for institutions seeking to modernise their imaging infrastructure.
Company Overview
Pro Medicus was founded in Melbourne in 1983, originally as a medical software and services company, before pivoting to imaging technology through the 2009 acquisition of German company Visage Imaging, which brought with it the intellectual property base that would become Visage 7. That acquisition proved to be one of the most value-creating corporate transactions in ASX history, as the Melbourne-based team systematically commercialised the Visage platform across the US hospital market over the following decade.
Today, ASX: PME operates primarily as a radiology technology company, with Visage 7 serving as a comprehensive enterprise imaging platform that covers radiology, cardiology, and other imaging-intensive specialties. The platform’s technical architecture is based on streaming technology that allows radiologists to access high-resolution images from any location with sufficient internet connectivity, without requiring local storage of large image files. This has become increasingly significant as healthcare systems consolidate, teleradiology expands, and remote reporting becomes a standard operational model.
The company maintains offices in Melbourne, San Diego, and Berlin, with the US market representing the dominant source of contract revenue. Its client list reads like a directory of American medical prestige — leading academic medical centres, major integrated health systems, and prominent paediatric hospitals have all committed to Visage 7 as their enterprise imaging platform. The concentration of top-tier institutions in the client base is itself a powerful signal about the platform’s standing in the market.
Sector Context
Medical imaging is one of the most fundamental tools of modern medicine. From the initial diagnosis of disease to the monitoring of treatment response and long-term disease surveillance, imaging studies — CT, MRI, PET, ultrasound, X-ray, and increasingly molecular imaging modalities — sit at the heart of clinical decision-making across virtually every medical specialty. The volume of imaging studies performed globally has grown consistently for decades and shows no signs of deceleration.
Several structural forces are sustaining and accelerating this growth. Ageing populations across developed markets are requiring more diagnostic imaging as age-related conditions become more prevalent. Expanding access to healthcare in both developed and emerging markets is broadening the patient base receiving diagnostic workups. The role of imaging in oncology — where it is essential for tumour detection, staging, treatment planning, and monitoring — is expanding as cancer incidence rises and treatment protocols become more imaging-intensive.
Artificial intelligence represents perhaps the most significant emerging dimension of the medical imaging software market. AI-powered image analysis tools — capable of assisting radiologists with detection, measurement, and classification of findings — are increasingly being integrated into imaging platforms, and the quality of the underlying viewing and workflow platform determines how effectively these tools can be embedded into clinical practice. ASX: PME has been thoughtful in its approach to AI integration within Visage 7, positioning the platform as an AI-ready infrastructure layer rather than a developer of specific AI algorithms, which allows it to work with the expanding ecosystem of radiology AI vendors without creating direct competitive tension.
Key News Catalyst
While Pro Medicus does not always generate single dramatic catalysts in the manner of a drug approval or resource discovery, the ongoing cadence of contract announcements constitutes a continuous news flow that keeps ASX: PME in the consciousness of the investment community. The company has demonstrated a consistent ability to win major health system contracts, with each announcement typically confirming a multi-year term, a minimum revenue commitment, and often a new segment of the market or geographic territory being opened up.
The broader context energising current investor interest is the combination of sustained contract growth and the ongoing evidence that Visage 7’s competitive position is, if anything, strengthening rather than eroding. As more leading institutions commit to the platform, the reference-site network available to Pro Medicus in sales conversations becomes more compelling, and the cost and disruption involved in ripping out an established Visage installation — to replace it with a competitor — grows over time. This creates a powerful installed-base dynamic that makes ASX: PME’s revenue increasingly defensible as the client list expands.
The company’s financial results have also continued to impress on the metrics that sophisticated investors in quality software businesses watch most closely: revenue growth, earnings before interest and tax (EBIT) margins, free cash flow conversion, and contract backlog. When all of these metrics move in the right direction simultaneously over an extended period, as they have at Pro Medicus, it speaks to genuine business quality rather than financial engineering.
Why Investors Are Watching
The sustained investor attention directed at Pro Medicus reflects a recognition that genuinely high-quality, durable growth businesses are rare assets in any sharemarket, and rarer still among ASX-listed companies with genuine global market leadership. ASX: PME ticks the boxes that quality-focused investors prize: a technically superior product in a structurally growing market, a recurring revenue model with high visibility, outstanding margins that compound over time, and a management team with a demonstrated track record of capital allocation discipline.
The valuation conversation around Pro Medicus is never simple. The stock consistently trades at a multiple that reflects its quality and growth prospects, and there is ongoing debate among analysts and investors about whether that multiple is appropriate or stretched. What keeps resolving the debate in the stock’s favour, historically, has been the company’s ability to keep growing into its valuation — adding contracts, expanding revenue, and maintaining margins in a way that repeatedly justifies a reassessment of the intrinsic value ceiling.
Global healthcare technology investors, including institutional funds that allocate across US, European, and Australian markets, have increasingly identified ASX: PME as a benchmark quality holding in the medical technology software space, which brings a depth of sophisticated investor support to the register that reinforces the stock’s resilience through market downturns.
Growth Drivers
The most direct growth driver for Pro Medicus is new contract wins and the revenue ramp of recently signed agreements. Large health system contracts typically have a transition and implementation phase before full imaging volumes flow through the Visage 7 platform, meaning that the revenue contribution from recently announced wins tends to build progressively over the initial years of a contract. This creates a visible backlog of growth embedded in the existing contract base even before any new wins are counted.
The US market remains the primary hunting ground for new contracts, and despite the company’s remarkable run of wins, a substantial portion of the US hospital market has not yet transitioned to Visage 7. The replacement cycle of legacy PACS systems continues to create opportunities, and as the reference site network expands, the sales conversations become progressively easier to close. Each prestigious institution that commits to the platform makes the next sales conversation more straightforward.
International expansion represents a meaningful incremental opportunity. While the US has been the dominant source of growth, ASX: PME has been building its presence in Europe and continues to evaluate opportunities in other markets. Australia, where the company has a home-market advantage, also represents an ongoing source of contract activity as local health networks modernise their imaging infrastructure.
The integration of AI tools with Visage 7 — both Pro Medicus’s own analytical capabilities and third-party AI applications that plug into the platform — creates opportunities to deepen the value delivered to customers and potentially expand the revenue per imaging study generated over time. As AI becomes standard practice in radiology workflows, the platform serving as the substrate for those workflows becomes more strategically embedded in clinical operations.
Risks and Watchpoints
Despite its exceptional track record, investors in Pro Medicus should maintain awareness of the risks that attend even the highest-quality businesses. Competitive risk is perennial — major global technology and healthcare IT companies have significant resources to invest in competing imaging platforms, and the success of Visage 7 has not gone unnoticed by rivals. If a credible competitive product emerges that can replicate Visage 7’s performance characteristics, the company’s win rate in new contract competitions could be affected.
Valuation risk is a recurring theme for ASX: PME precisely because the stock’s quality is well-recognised. A premium valuation creates a higher bar for earnings growth, and any short-term miss relative to market expectations — whether due to contract timing, implementation delays, or macroeconomic factors affecting healthcare capital spending — can result in significant share price volatility, even if the underlying business trajectory remains intact.
Currency exposure matters for a company generating the majority of its revenue in US dollars. Movements in the AUD/USD exchange rate affect the reported value of Pro Medicus’s US revenue when translated back into Australian dollars, and a significantly stronger Australian dollar would reduce the reported benefit of US contract wins.
Customer concentration risk, while diminishing as the contract base broadens, remains relevant. If a significant health system client were to undergo financial distress, merger-driven platform consolidation, or management change that prompted a reassessment of their technology vendors, the impact on Pro Medicus’s revenue could be material. The multi-year contract structures provide some protection, but they are not absolute guarantees.
Long-Term Outlook
The long-term investment thesis for Pro Medicus is, at its core, uncomplicated: a structurally growing imaging market, a technically superior platform with no obvious successor threatening its position, a recurring revenue model with compounding installed-base dynamics, and a management team with the discipline to continue executing. These factors, sustained over time, create the conditions for exceptional long-term value creation.
The medical imaging software market will continue evolving around AI, cloud computing, and interoperability standards, and how ASX: PME navigates those transitions will shape its competitive position into the 2030s. The company’s track record of technical investment — most evidently in the cloud-native streaming architecture that differentiates Visage 7 from legacy competitors — suggests a capacity for continued innovation that should help it stay ahead of the curve.
For investors who have been watching Pro Medicus from the sidelines, the perpetual dilemma is that waiting for a more affordable entry point has historically meant waiting indefinitely as the company continues to grow. For those already holding ASX: PME, the question is whether the quality and growth trajectory justify the ongoing patience and concentration required. The evidence of the past decade suggests it has.
Conclusion
Pro Medicus (ASX: PME) occupies a position that few ASX-listed companies ever achieve: genuine global market leadership in a growing, defensible technology category, delivered through a business model that compounds returns with remarkable consistency. The reasons investors keep watching ASX: PME are as straightforward as they are compelling — a world-class product, a structurally attractive market, and a management team that has proven over many years its capacity to convert scientific and technical quality into outstanding commercial outcomes. Whether the entry point at any given moment represents value is a judgment call that every investor must make independently, but the quality of what Pro Medicus has built leaves very little room for doubt.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
ASX Listed Companies Research Reports
Get weekly insights on stock picks, fund performance, and market trends.
No spam. Unsubscribe anytime.
Make Kalkine
My Trusted Source
Suite 202, 234 George Street, Sydney, New South Wales, Australia, 2000
(02) 90559490, (02) 90559496, (02) 86673147
[email protected]
[email protected]
Mon – Fri [9:30 – 18:30]
Never miss latest news and offers
Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2604166) and the PCI DSS Level 1 Version 4.0.1 certification (Certificate No. CSNDPCI9161).
Disclaimer
The information on this website is provided by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). Any information or advice provided on this website is general advice only and does not take into account any of your personal objectives, circumstances or needs. You should therefore consider whether the advice is appropriate for your objectives, financial situation and needs before acting upon it. There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities and financial products we outline on the website You should obtain a copy of the relevant Offer Document before making any decision about whether to acquire the security or product. Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional adviser. Please also read our Terms & Conditions and Financial Services Guide for further information. Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Returns stated do not take into account transaction costs and taxes. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors. The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Kalkine does not issue, sell or deal in any financial products.
Copyright © 2026 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Our analysts regularly publish research covering sectors, trends, and broader market developments.
Leave a Reply